FAMPYRA (fampridine), voltage-dependent potassium channel blocker
NEUROLOGY - Update
Opinions on drugs -
Posted on
Feb 20 2019
Reason for request
Renewal of inclusion
Low clinical benefit in the management of walking disorders in multiple sclerosis patients
-
FAMPYRA has been granted a marketing authorisation for the improvement in walking ability of patients suffering from multiple sclerosis (MS) and presenting with a walking handicap (EDSS 4-7).
-
The data derived from a new phase III study have confirmed its modest efficacy versus placebo on walking ability, along with the existence of a small fraction of responders that cannot be identified beforehand.
-
Its tolerance profile is marked by high, though relatively infrequent risks of convulsions, severe hypersensitivity and urinary tract infection.
-
It failed to improve the quality of life of the patients in the clinical studies.
Clinical Benefit
Low |
- |